Nitrosyl-heme Formulations for Treating Cardiovascular Conditions and Hemolysis

University of Pittsburgh researchers have developed innovative nitrosyl-heme formulations that combine nitric oxide (NO)-heme complexes with albumin and a thiol (e.g., glutathione, cysteine) to induce vasodilation and treat a wide range of human pathological conditions. These formulations have potential applications in cardiovascular diseases, respiratory failure, metabolic syndrome, diabetes, lipid disorders, inflammation, aging, and infectious diseases.

NO- ferroheme in albumin administered intravenously in both hypoxic (A) and normoxic (B) mice results in robust, dose-dependent vasodilation at low- to mid-nanomolar concentrations in circulation.

Description

The nitrosyl-heme formulations developed by the researchers involve the combination of NO-heme complexes with albumin and thiols. This combination induces vasodilation and can be used to treat various cardiovascular and respiratory conditions, as well as metabolic and inflammatory diseases. The formulations also have the potential to neutralize free heme associated with hemolysis and stabilize free-heme proteins. The technology includes a method for manufacturing stable ferro-heme molecules, which enhances the therapeutic potential of these formulations.

Applications

• Cardiovascular conditions (e.g., hypertension, heart failure)
• Respiratory failure (e.g., acute respiratory distress syndrome)
• Metabolic and inflammatory diseases
• Hemolytic conditions (e.g., sickle cell anemia)

Advantages

This technology offers a novel vasodilation agent with a stable and potent molecule, providing a new therapeutic approach for treating a wide range of pathological conditions. The formulations can neutralize free heme associated with hemolysis and stabilize free-heme proteins, reducing the deleterious effects of free heme release. The method for creating stable NO-heme complexes further enhances the therapeutic potential, making it a promising candidate for managing cardiovascular diseases, respiratory failure, and hemolytic conditions.

Invention Readiness

The invention is currently supported by in vivo data demonstrating the efficacy of the nitrosyl-heme formulations in inducing vasodilation and treating various pathological conditions. Further development includes optimizing the formulations and testing their therapeutic effects in biologically and clinically relevant animal models.

IP Status

https://patents.google.com/patent/WO2024112490A2